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Abstract. Core binding factor (CBF) acute myeloid leukaemia 
(AML) represents 5-8% of all AMLs and has a relatively 
favourable prognosis. However, activating c-KIT mutations 
are reported to be associated with higher risk of relapse and 
shorter survival. To verify the incidence and prognostic value 
of c-KIT mutations in CBF AML, we retrospectively analysed 
bone marrow samples of 23 consecutive adult patients with 
de novo CBF AML [14 inv(16) and 9 t(8;21)] treated at a single 
institution from 2000 to 2011. All patients received standard 
induction chemotherapy with cytarabine, idarubicin and etopo-
side; 13 underwent allogeneic stem cell transplantation. c-KIT 
mutations in exons 8, 9, 10, 11, 13, 14 and 17 were assessed 
by PCR amplification in combination with direct sequencing. 
c-KIT mutations (3 in exon 10 and 4 in exon 17) were detected 
in 7/23 (30.4%) patients, 3 with t(8;21) and 4 with inv(16). No 
difference in c-KIT mutation status was observed between 
cases with inv(16) or t(8;21) alone and cases with additional 
cytogenetic abnormalities. No association between gender, 
age, white blood cell and platelet count, peripheral blood and 
bone marrow blast cells at diagnosis, achievement of complete 
remission, cytogenetic risk groups and Wilms tumour gene 1 
(WT1) levels was found. On the contrary, lactate dehydroge-
nase (LDH) values were higher in mutated than in non-mutated 
patients (P=0.01). Overall survival (OS) rates were longer in 
CBF compared to the other types of AML and disease-free 
survival (DFS) was longer in inv(16) than in t(8;21) AML. OS 
and DFS were similar in mutated and non-mutated CBF AML 
patients. Our results confirm a better prognosis for CBF AML 
than all other AML categories, and for inv(16) than t(8;21) 
AML. However, no prognostic value for c-KIT mutational 
status was found in our series. The association between LDH 
levels and c-KIT mutation would indicate a more active prolif-
eration for mutated CBF AML.
Introduction
RUNX1-RUNX1T1 [t(8;21)] or CBFB-MYH11 [inv(16)] 
fusion transcripts identify the core binding factor (CBF) 
acute myeloid leukaemia (AML). Both t(8;21) and inv(16) are 
characterised at the molecular level by disruption of genes 
encoding different subunits of CBF (1). CBF AML represents 
5-8% of all AML (2) and has a relatively favourable prognosis, 
following treatment with high dose cytarabine in the consoli-
dation phase (3-5). Mutations of c-KIT occur in 20-25% of 
t(8;21) and in approximately 30% of inv(16) cases (6). In CBF 
AML, c-KIT mutations occur frequently within exon 17, 
which encodes the activation loop in the kinase domain, and 
in exon 8, which encodes the extracellular portion of the KIT 
receptor (7). Older age, CD56 expression and activating c-KIT 
mutations are reported to be associated with higher incidence 
of relapse and lower survival (6,8,9) while inv(16) patients with 
+22 secondary abnormality have a better prognosis (10,11). 
However, no significant differences in overall survival (OS) 
rates according to c-KIT mutation status have been reported in 
CBF AML patients (12). In the present study, we retrospectively 
analysed 23 patients with CBF AML in order to investigate the 
incidence and prognostic value of c-KIT mutations.
Materials and methods
Patients. Two hundred and forty-nine consecutive unselected 
adult patients with newly diagnosed AML were admitted 
to the Division of Haematology, Città della Salute e della 
Scienza, University of Turin, Italy, from 2000 to 2011. Among 
these, 23 patients (12 female and 11 male) with de novo 
CBF AML were retrospectively examined. The mean age 
was 42.7 years (range, 19-64). Diagnosis of CBF AML was 
performed according to the WHO criteria (2). Inv(16) was 
present in 14 patients (60.8%), 9 with isolated inv(16) and 
5 with additional cytogenetic abnormalities. Nine patients 
(39.2%) showed t(8;21); 7 had isolated t(8;21) and 2 t(8;21) 
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with additional cytogenetic aberrations. All patients received 
standard induction chemotherapy with cytarabine, idarubicin 
and etoposide (ICE), followed by consolidation treatment with 
high-dose cytarabine. Thirteen patients with suitable HLA 
matched donors (related or unrelated) underwent allogeneic 
stem cell transplantation in first (10 cases) or second (3 cases) 
remission. To avoid confounding effect of the transplant proce-
dure, patients were censored at the time of the transplantation. 
General informed consent was obtained according to the local 
Ethics Committee guidelines. Samples were numerically iden-
tified, maintaining patient anonymity.
Molecular analysis. c-KIT mutations in exons 8, 9, 10, 11, 13, 
14 and 17 were assessed by polymerase chain reaction (PCR) 
amplification in combination with direct sequencing from 
bone marrow (BM) samples.
Amplification of c-KIT exons was performed by PCR 
with specific oligonucleotide primers (Table I) (13-15), and 
DNA sequencing was executed using the cDNA from AML 
BM samples. Sequencing reactions were carried out using 
the BigDye Terminator Cycle Sequencing Ready Reaction 
kit (Applied Biosystems, Foster City, CA, USA), and the 
analysis was performed on an ABI 3130 automated capillary 
system. FLT3-ITD and D835 mutation status was determined 
by conventional PCR and direct sequencing (16) and NPM1 
mutation status was determined by PCR-capillary electro-
phoresis methods (17), followed by direct sequencing for 
positive sample characterization (18) (primers in Table I). The 
electropherograms were compared to published germ-line 
sequences using basic local alignment search tool (BLAST) 
on the Internet. Wilms tumour gene 1 (WT1) expression was 
quantified using a real-time quantitative PCR (WT1 ELN kit, 
Nanogen, Buttigliera Alta, Turin, Italy).
Histology. Formalin-fixed, paraffin-embedded BM biop-
sies were stained with H&E, Dominici, Perls, reticulin and 
immunostained with monoclonal antibodies anti-CD2, CD13, 
CD33, CD34, CD56 (all from Novocastra, Newcastle, UK), 
anti-human nucleophosmin, CD68PGM1, and polyclonal 
antibodies anti-human myeloperoxidase and CD117 (all from 
Dako, Glostrup, Denmark) (Figs. 1 and 2).
Statistical analysis. The association between c-KIT mutation 
and clinical or haematological parameters was assessed by the 
one-way analysis of variance (ANOVA) and the Fisher's exact 
test. Univariate survival analyses were based on Kaplan-Meier 
Table I. Primer sequences for mutation analysis.
 Sequences
FLT3 ITD F: TGTCGAGCAGTACTCTAAACA
 R: ATCCTAGTACCTTCCCAAACTC
FLT3 D835 F: CCGCCAGGAACGGCTTG 
 R: GCAGACGGGCATTGCCCC
NPM-I11f-FAM GTGGTAGAATGAAAAATAGAT
NPM-E12r CTTGGCAATAGAACCTGGAC
NPM1 F: TGGTTCTCTTCCCAAAGTGG
 R: CCTGGACAACATTTATCAAACACG
CK9 F: TCCTAGAGTAAGCCAGGGCTT
 R: TGGTAGACAGAGCCTAAACATCC
CK11 F: CCAGAGTGCTCTAATGACTG
 R: AGCCCCTGTTTCATACTGAC
CK13 F: GCTTGACATCAGTTTGCCAG
 R: AAAGGCAGCTTGGACACGGCTTTA
CK17 F: TGAACATCATTCAAGGCGTACTTTTG
 R: TTGAAACTAAAAATCCTTTGCAGGAC
CK14 F: TCTCACCTTCTTTCTAACCTTTTC
 R: AACCCTTATGACCCCATGAA
KIT10 F: TGCCAAAGTTTGTGATTCCA
 R: GTGGGGAGAAAGGGAAAAAT
CKIT8 F: GCAGCCTCAGGAAGGTTGTA
 R: AATTGCAGTCCTTCCCCTCT
F, forward; R, reverse.
Figure 1. Inv(16) AML (FAB M4 Eo). Bone marrow biopsy (Dominici's 
staining, x600) showing proliferation of both neutrophil and monocyte pre-
cursors, and abnormal eosinophils with basophilic granules. (Inset, Giemsa 
staining, x1,000).
Figure 2. Inv(16) AML. Blasts expressing MPO, CD34, CD68PGM1 and 
intranuclear NPM. (Bone marrow biopsy; immunoperoxidase staining, x600).
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product-limit estimates of survival distribution, and differences 
between survival curves were tested using the Cox-Mantel test.
Results
c-KIT mutations were detected in 7/23 (30.4%) patients. M541L 
mutation (exon 10) was found in 3 samples and D816V or D816H 
or D816Y mutation (exon 17) in 4. Two SNPs (K546K and I798I) 
were detected in 6 AML samples (Table II). c-KIT mutation 
electropherograms are shown in Fig. 3. FLT3 ITD, FLT3 D835 
and NPM1 mutations rarely occurred (data not shown). 
Association between c-KIT mutation and clinical and haema-
tological characteristics. c-KIT mutations were detected in 
3/9 (33.3%) patients with t(8;21) and in 4/14 (28.6%) patients 
with inv(16). No significant difference in c-KIT mutation was 
Table II. c-KIT mutations observed in 23 CBF AML cases.
 No. of cases c-KIT mutated Mutation type c-KIT negative (polymorphism) Polymorphism
t(8;21) 9 3 D816H (exon 17) 6 (3) I798I
   D816V (exon 17)  I798I
   M541L (exon 10)  I798I, K546K
     (simultaneous)
inv(16) 14 4 D816Y (exon 17) 10 (3) K546K
   D816V (exon 17)  I798I
   M541L (exon 10)  K546K
   M541L (exon 10)
Total 23
Table III. Association between c-KIT mutations and t(8;21) AML (N=9).
 No. of cases t(8;21) alone t(8;21) plus additional cytogenetic abnormalities P-value
Mutation 3 2 1 0.58
No mutation 6 5 1
Total 9 7 2
Table IV. Association between c-KIT mutations and inv(16) AML (N=14).
 No. of cases inv(16) alone inv(16) plus additional cytogenetic abnormalities P-value
Mutation 4 2 2 0.45
No mutation 10 7 3
Total 14 9 5
Figure 3. c-KIT mutation electropherograms. Representation of peaks corresponding to wild-type (wt) and mutant c-KIT alleles (indicated by arrows) in 
chromatograms of cDNA from leukaemic cells of the seven mutated cases in exon 10 or 17. Wt sequences of control cases are also reported. 
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found between cases with t(8;21) or inv(16) alone and cases 
with additional cytogenetic aberrations (Tables III and IV).
c-KIT mutation status was not associated with gender, age, 
white blood cell and platelet count, percentage of peripheral 
blood and bone marrow blasts at diagnosis, cytogenetic risk 
groups and WT1 levels. Also, no association was found for 
the achievement of complete remission (CR), although the 
two patients who did not achieve CR were non-mutated. On 
the contrary, lactate dehydrogenase (LDH) levels were higher 
(1386 UI/l) in c-KIT mutated than in non-mutated patients 
(753 UI/l; P=0.01) (Table V).
Correlation of c-KIT mutation with overall and disease-free 
survival. In the 23 CBF AML patients OS was significantly 
longer than in the 226 patients with other types of AML 
treated at the same institution during the same period; at the 
10-year follow-up, 57% of CBF AML patients were alive 
compared to 24% of patients with all other AML categories 
(P=0.0004) (Fig. 4).
No difference in OS was found between inv(16) and t(8;21) 
CBF AML; after 88 months, 76% of inv(16) and 60% of t(8;21) 
patients were alive, respectively (P=0.6). However, DFS for 
inv(16) AML was significantly longer than that for t(8;21) 
Table V. Association between c-KIT mutation and clinical and haematological characteristics in CBF AML (N=23).
 c-KIT mutated (n=7) c-KIT non mutated (n=16)
 ----------------------------------------- --------------------------------------------------
Variables No. of cases Mean ± SD Mean ± SD P-value
Age (years) 23 51±11.2 39±13.4 0.06
WBC count (x109/l) 23 34.045±33.9 21.702±19.918 0.3
Plt count (x109/l) 23 30.428±31.320 46.133±24.023 0.2
LDH (UI/l) 23 1,386±629 753±312 0.01
PB blasts (%) 23 48.43±23.04 54.92±19.67 0.5
BM blasts (%) 23 48.85±24.88 60.64±14.25 0.17
WT1 (number of WT1 copies/104 ABL copies) 15 17,307±22,628 (4) 15,687±17,780 (11) 0.8
Gender
  Male 11 3/7 8/16
  Female 12 4/7 8/16 0.5
Cytogenic risk
  Low 18 6/7 12/16
  High 5 1/7 4/16 0.5
Remission
  Complete remission 21 7/7 14/16
  No remission 2 0/7 2/16 0.5
WBC, white blood cell; Plt, platelet; LDH, lactate dehydrogenase; PB, peripheral blood; BM, bone marrow; WT1, Wilms tumour gene.
Figure 4. Overall survival of patients with CBF AML and other types of AML. Figure 5. Disease-free survival for patients with inv(16) and t(8;21) AML.
ONCOLOGY REPORTS  29:  1867-1872,  2013 1871
cases; after 88 months, 67% of inv(16) patients were free of the 
disease, vs. 20% of those with t(8;21) (P=0.04) (Fig. 5).
No difference in OS was found when CBF AML patients 
were categorised according to c-KIT mutation; after 88 months, 
78% of c-KIT non-mutated and 68% of mutated patients were 
alive, respectively (P=0.9) (Fig. 6). DFS was similar in c-KIT 
mutated and non-mutated CBF AML patients (P=0.6).
Discussion
Our results showed an overall incidence of c-KIT mutation in 
30.4% of cases, as previously reported in adult CBF AML (6), 
and a better prognosis for CBF AML than for cytogenetically 
normal or other subtypes of AML, which is in agreement 
with previous data (19,20). In our study, inv(16) AML had a 
significantly longer DFS than t(8;21) AML, consistent with 
previous reports demonstrating that patients with t(8;21) have 
significantly shorter survival times after relapse than patients 
with inv(16), possibly related to a lower response to salvage 
treatment in patients with t(8;21) (10,11,21).
c-KIT mutations in our CBF AMLs were associated with 
higher LDH levels, suggesting a possible prognostic role. It 
is well known that high LDH values are associated with a 
poorer outcome both in AML and myelodysplastic syndromes 
(MDS) (22-24). This was observed in our study as well; when 
cases were categorised according to the median LDH value 
(880 UI/l), all patients with higher LDH values relapsed after 
15 months, while 84% of patients with lower LDH values 
were free of the disease. However, possibly due to the small 
number of cases, the result is only of borderline significance 
(P=0.1) (Fig. 7). The association between c-KIT mutation and 
LDH levels is likely to indicate a more active proliferation in 
mutated CBF AML.
Contrary to most published studies, no association was found 
in our CBF AML group between c-KIT mutations and achieve-
ment of CR, OS and DFS; this may be due to the small number 
of cases and to considering CBF AML as a single group. Indeed, 
previous reports showed a prognostic value of c-KIT mutations 
in t(8;21) but not in inv(16) CBF AML (7,25). Therefore, t(8;21) 
and inv(16) AML should be regarded as distinct clinical entities 
to be stratified and reported separately, as already suggested (11), 
and possibly treated with a tailored approach (26).
Therefore, further studies are required to clarify the prog-
nostic value of c-KIT mutations in newly diagnosed adult AML.
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